In two trials of linaclotide, about 21 percent of participants with chronic constipation had at least three spontaneous bowel movements a week, compared with no more than 6 percent taking a placebo.
The drug, a minimally absorbed peptide agonist of the guanylate cyclase C receptor, also helped reduce abdominal discomfort, bloating and the severity of constipation.
Read the New England Journal of Medicine report on the drug linaclotide for chronic constipation.
Related Articles on Constipation:
25-50% of Older Americans Experience Pain, Many Untreated
Henry Ford Hospital: Pill Reduces Prep Needed for Colonoscopy
Rome Foundation Releases New Tool for Diagnosis of Common GI Symptoms
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
